Y-Intercept (HK)
VKTX icon

Y-Intercept (HK)’s Viking Therapeutics VKTX Stock Holding History

Y-Intercept (HK)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$270K Sell
8,272
-64,168
-89% -$2.22M 0.01% 1427
2026
Q2 		$2.83M Buy
+72,440
New +$2.34M 0.06% 505
2025
Q2 		– Sell
-27,911
Closed -$674K – 2052
2025
Q1 		$674K Buy
+27,911
New +$882K 0.05% 570
2024
Q1 		– Sell
-11,812
Closed -$220K – 1788
2023
Q4 		$220K Buy
+11,812
New +$154K 0.02% 967

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Y-Intercept (HK)'s VKTX Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Viking Therapeutics (VKTX) stake by 89% in Q3 2026, selling an estimated $2.22M and leaving 8,272 shares worth $270K. The position accounts for 0.01% of the portfolio, ranked #1427.

Y-Intercept (HK) first reported a position in VKTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.83M in Q2 2026. 221 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Y-Intercept (HK) held 8,272 shares of Viking Therapeutics worth $270K as of Q3 2026.
  • Y-Intercept (HK) sold 64,168 Viking Therapeutics shares in Q3 2026, an estimated $2.22M.
  • Viking Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1427 holding.
  • Y-Intercept (HK) first reported a position in Viking Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Y-Intercept (HK)'s Viking Therapeutics position peaked at $2.83M in Q2 2026.
  • 221 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.